Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) Given Consensus Recommendation of “Buy” by Brokerages

Centessa Pharmaceuticals PLC Sponsored ADR (NASDAQ:CNTA) has received an average recommendation of “Buy” from the fourteen ratings firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $38.6364.

CNTA has been the subject of several recent analyst reports. Oppenheimer boosted their price objective on shares of Centessa Pharmaceuticals from $40.00 to $62.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 21st. Piper Sandler reissued an “overweight” rating on shares of Centessa Pharmaceuticals in a report on Friday, January 16th. TD Cowen reaffirmed a “buy” rating on shares of Centessa Pharmaceuticals in a report on Wednesday, January 14th. Finally, Chardan Capital reiterated a “buy” rating and set a $30.00 target price on shares of Centessa Pharmaceuticals in a research report on Friday, January 2nd.

Insider Buying and Selling at Centessa Pharmaceuticals

In other news, insider Iqbal J. Hussain sold 38,951 shares of the stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $25.15, for a total value of $979,617.65. Following the completion of the sale, the insider owned 57,645 shares of the company’s stock, valued at $1,449,771.75. This represents a 40.32% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Mario Alberto Accardi sold 10,000 shares of the business’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $30.00, for a total transaction of $300,000.00. Following the completion of the sale, the insider owned 178,801 shares in the company, valued at approximately $5,364,030. This trade represents a 5.30% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 49,961 shares of company stock worth $1,304,878. Insiders own 7.09% of the company’s stock.

Institutional Investors Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of CNTA. TD Waterhouse Canada Inc. acquired a new stake in shares of Centessa Pharmaceuticals in the 4th quarter valued at $25,000. Caitong International Asset Management Co. Ltd acquired a new stake in Centessa Pharmaceuticals in the fourth quarter valued at $36,000. T. Rowe Price Investment Management Inc. lifted its holdings in Centessa Pharmaceuticals by 7,580.0% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,536 shares of the company’s stock worth $39,000 after buying an additional 1,516 shares during the last quarter. Wells Fargo & Company MN lifted its holdings in Centessa Pharmaceuticals by 42.4% during the 4th quarter. Wells Fargo & Company MN now owns 3,387 shares of the company’s stock worth $85,000 after buying an additional 1,008 shares during the last quarter. Finally, Knott David M Jr acquired a new position in shares of Centessa Pharmaceuticals during the 4th quarter worth about $100,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

Centessa Pharmaceuticals Stock Up 1.7%

Shares of NASDAQ CNTA opened at $26.97 on Thursday. Centessa Pharmaceuticals has a 52-week low of $9.60 and a 52-week high of $30.58. The company has a debt-to-equity ratio of 0.36, a quick ratio of 10.57 and a current ratio of 10.56. The stock has a 50 day moving average price of $24.29 and a 200 day moving average price of $23.49. The firm has a market capitalization of $3.94 billion, a price-to-earnings ratio of -14.74 and a beta of 1.56.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc is a global clinical‐stage biopharmaceutical company focused on the discovery and development of innovative therapies across multiple disease areas. The company operates a modular R&D network, bringing together a portfolio of independent, specialist research entities under a single corporate umbrella. This structure is designed to accelerate decision‐making and resource allocation while leveraging deep scientific expertise in each therapeutic domain.

Centessa’s pipeline spans oncology, immunology, neuroscience, cardiovascular and metabolic diseases, as well as rare genetic disorders.